Matthew Harrison analyst MORGAN STANLEY

Currently out of the existing stock ratings of Matthew Harrison, 359 are a BUY (61.05%), 167 are a HOLD (28.4%), 62 are a SELL (10.54%).

Matthew Harrison

Work Performance Price Targets & Ratings Chart

Analyst Matthew Harrison works at MORGAN STANLEY with a stock forecast success ratio of 66.26% fulfilled within 188.81 days on average.

Matthew Harrison’s has documented 1,354 price targets and ratings displayed on 88 stocks. The coverage is on Healthcare, Technology, Basic Materials, Energy sectors.

Most recent stock forecast was given on GMAB, Genmab AS at 26-Mar-2024.

Wall Street Analyst Matthew Harrison

Analyst best performing recommendations are on CMRX (CHIMERIX).
The best stock recommendation documented was for CMRX (CHIMERIX) at 2/23/2016. The price target of $5 was fulfilled within 1 day with a profit of $0.54 (12.11%) receiving and performance score of 121.08.

Average potential price target upside

ADCT ADC Therapeutics SA ADGI Adagio Therapeutics ALVR Allovir  ALXN Alexion Pharmaceuticals AMGN Amgen ARGX argenx NV ADR AVIR Atea Pharmaceuticals  BGNE BeiGene Ltd BHVN Biohaven Pharmaceutical Holding Co Ltd BIIB Biogen BLUE Bluebird bio BMRN Biomarin Pharmaceutical BMY Bristol-Myers Squibb Company BNTX BioNTech SE CCMP CMC Materials CELG Celgene DNLI Denali Therapeutics EVLO Evelo Biosciences FULC Fulcrum Therapeutics FUSN Fusion Pharmaceuticals  GBT Global Blood Therapeutics GLPG Galapagos NV ADR HUN Huntsman IMGN ImmunoGen INSM Insmed KLDO Kaleido Biosciences KOD Kodiak Sciences LEGN Legend Biotech Corp MRK Merck mpany MRNA Moderna PFE Pfizer PTLA Portola Pharmaceuticals REGN Regeneron Pharmaceuticals RPM RPM International SGEN Seagen SGTX Sigilon Therapeutics  SRPT Sarepta Therapeutics VRTX Vertex Pharmaceuticals VVV Valvoline ABBV AbbVie GILD Gilead Sciences JNJ Johnson & Johnson RDUS Schnitzer Steel Industries SAGE Sage Therapeutic ALNY Alnylam Pharmaceuticals CERE Cerevel Therapeutics Holdings CNTA Centessa Pharmaceuticals PLC ADR EDIT Editas Medicine FUL H B Fuller Company GMAB Genmab AS IMMU Immunomedics IMRA Imara LLY Eli Lilly and Company RGNX Regenxbio TSVT 2Seventy Bio ADAG Adagene AKRO Akero Therapeutics BOLT Bolt Biotherapeutics PHVS Pharvaris BV VACC XLRN Acceleron Pharma ALEC Alector CABA Cabaletta Bio CYTK Cytokinetics INCY yte RUBY Rubius Therapeutics ZNTL Zentalis Pharmaceuticals Llc SANA Sana Biotechnology TNYA Tenaya Therapeutics APD Air Products and Chemicals AXTA Axalta Coating Systems Ltd CMRX Chimerix ENTG Entegris FTSV Forty Seven GRA W. R. Grace INVA Innoviva IOBT IO Biotech IVVD Invivyd . KOP Koppers Holdings KWR Quaker Chemical LYEL Lyell Immunopharma MTX Minerals Technologies SHW Sherwin-Williams Co UBX Unity Biotechnology VIGL Vigil Neuroscience DBVT DBV Technologies LIN Linde plc Ordinary Shares FMC FMC

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

8

$2.91 (57.17%)

1 months 26 days ago

0/6 (0%)

$2.86 (55.64%)

Buy

9

$3.91 (76.82%)

3

2 months 1 days ago

1/7 (14.29%)

$4.18 (86.72%)

70

Sell

1

$-4.09 (-80.35%)

2

6 months 4 days ago

2/4 (50%)

$0.23 (29.87%)

30

Hold

5

8 months 11 days ago

1/2 (50%)

$-0.07 (-1.38%)

2

Buy

10

8 months 12 days ago

0/4 (0%)

$7.6 (316.67%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Matthew Harrison is most bullish on?

Potential upside of $176.52 has been obtained for REGN (REGENERON PHARMACEUTICALS)

Which stock is Matthew Harrison is most reserved on?

Potential downside of -$40.22 has been obtained for VRTX (VERTEX PHARMACEUTICALS)

What Year was the first public recommendation made by Matthew Harrison?

On 2012

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?